Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)

Topics Lawsuit

March 06, 2023

From Bernstein Liebhard LLP

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

March 02, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm

Topics Lawsuit

March 01, 2023

From Bragar Eagel & Squire

NASDAQ: CRBU Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Caribou Biosciences, Inc. ↗

February 28, 2023

San Diego, CA -- (SBWIRE) -- 02/28/2023 -- An investor, who purchased shares of Caribou Biosciences, Inc. (NASDAQ: CRBU), filed a lawsuit over alleged violations of Federal Securities Laws by Caribou...

Via SBWire

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

February 26, 2023

WHY: New York, NY - (NewMediaWire) - February 26, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm

Topics Lawsuit

February 24, 2023

From Bragar Eagel & Squire

ROSEN, A LEADING AND RANKED FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

February 23, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Caribou Biosciences, Inc. (CRBU) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Caribou Biosciences, Inc.

Topics Lawsuit

February 22, 2023

From Robbins LLP

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

There's a Lot of Upside For Emerging Gene-Editing Companies

February 21, 2023

Via MarketBeat

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm

February 19, 2023

From Bragar Eagel & Squire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

February 19, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Lowey Dannenberg Notifies Caribou Biosciences, Inc. (Nasdaq: CRBU) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline

Topics Lawsuit

February 17, 2023

From Lowey Dannenberg, P.C.

CARIBOU ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. and Encourages Investors to Contact the Firm

February 14, 2023

From Bragar Eagel & Squire, P.C.

Bronstein, Gewirtz & Grossman, LLC Notifies Caribou Biosciences, Inc. (CRBU) Investors of Class Action and to Actively Participate

February 14, 2023

From Bronstein, Gewirtz & Grossman, LLC

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Caribou Biosciences, Inc. (CRBU)

February 13, 2023

From Robbins LLP

CRBU INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CRBU

February 13, 2023

From Rosen Law Firm

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the Firm

February 13, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Caribou Biosciences, Inc. with Losses of $100,000 to Contact the Firm

February 11, 2023

Caribou Biosciences to Participate in Upcoming Investor Conferences

February 01, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗

January 25, 2023

Via InvestorPlace

Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

December 28, 2022

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

December 27, 2022

Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

December 12, 2022

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

December 12, 2022

Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗

December 08, 2022

-Clinical Data Due Next Week at ASH-

Via Benzinga

Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

December 01, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug...

Via FinancialNewsMedia

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy

November 29, 2022

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

November 21, 2022